Jonathan Chernoff

Transformation suppression by protein tyrosine phosphatase 1B requires a functional SH3 ligand.

p21-activated kinase 1 (Pak1) regulates cell motility in mammalian fibroblasts.

Regulation of macropinocytosis by p21-activated kinase-1.

Lentivirus Nef specifically activates Pak2.

Temporal and spatial distribution of activated Pak1 in fibroblasts.

p21-activated kinase links Rac/Cdc42 signaling to merlin.

The evolutionary history of effectors downstream of Cdc42 and Rac.

p21-activated kinases: three more join the Pak.

Interaction of protein tyrosine phosphatase (PTP) 1B with its substrates is influenced by two distinct binding domains.

p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells.

Cell cycle-regulated phosphorylation of p21-activated kinase 1.

Detection of peptides, proteins, and drugs that selectively interact with protein targets.

High midsummer for small GTPases.

Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration.

Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rho-GEF kalirin.

Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase.

p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest.

p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD.

Protein-tyrosine phosphatase 1B mediates the effects of insulin on the actin cytoskeleton in immortalized fibroblasts.

Pak1 and PIX regulate contact inhibition during epithelial wound healing.

NF2: the wizardry of merlin.

AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter.

P21-activated protein kinase 1 (Pak1) mediates the cross talk between insulin and β-catenin on proglucagon gene expression and its ablation affects glucose homeostasis in male C57BL/6 mice.

Protein-tyrosine phosphatase 1B as a potential drug target for obesity.

Vav1 transduces T cell receptor signals to the activation of the Ras/ERK pathway via LAT, Sos, and RasGRP1.

Analysis and manipulation of intracellular signaling cascades.

The cross-Rho'ds of cell-cell adhesion.

The genetics of Pak.

Rho-GTPases: new members, new pathways.

Spatially distinct binding of Cdc42 to PAK1 and N-WASP in breast carcinoma cells.

Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration in squamous carcinoma cells.

Essential role of CIB1 in regulating PAK1 activation and cell migration.

Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors.

Pak GITs to Aurora-A.

Crystal structure of a complex between protein tyrosine phosphatase 1B and the insulin receptor tyrosine kinase.

Production and use of a cell permeable inhibitor of group A Paks (TAT-PID) to analyze signal transduction.

Regulation of the catalytic activity of PTP1B: roles for cell adhesion, tyrosine residue 66, and proline residues 309 and 310.

Targeting and activation of Rac1 are mediated by the exchange factor beta-Pix.

Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic properties.

A dimeric kinase assembly underlying autophosphorylation in the p21 activated kinases.

Src transforms in a Cool way.

Regulation of protein tyrosine phosphatase 1B by sumoylation.

Specificity profiling of Pak kinases allows identification of novel phosphorylation sites.

alpha6beta4 integrin activates Rac-dependent p21-activated kinase 1 to drive NF-kappaB-dependent resistance to apoptosis in 3D mammary acini.

Regulation of Akt/PKB activity by P21-activated kinase in cardiomyocytes.

A tale of two Paks.

An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.

Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells.

PAK1-mediated activation of ERK1/2 regulates lamellipodial dynamics.

p21-activated kinase regulates mast cell degranulation via effects on calcium mobilization and cytoskeletal dynamics.

PAK kinase regulates Rac GTPase and is a potential target in human schwannomas.

Alphaherpesvirus US3-mediated reorganization of the actin cytoskeleton is mediated by group A p21-activated kinases.

Activation of Src by protein tyrosine phosphatase 1B Is required for ErbB2 transformation of human breast epithelial cells.

The DeMSTification of mammalian Ste20 kinases.

Interaction with LC8 is required for Pak1 nuclear import and is indispensable for zebrafish development.

Group I p21-activated kinases: emerging roles in immune function and viral pathogenesis.

An emerging role for p21-activated kinases (Paks) in viral infections.

PTP1B: a double agent in metabolism and oncogenesis.

Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A.

A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma.

A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.

LOV conquers (sm)All GTPases.

The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.

p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.

Getting smart about p21-activated kinases.

Back to the future: proceedings from the 2010 NF Conference.

Identification of the atypical MAPK Erk3 as a novel substrate for p21-activated kinase (Pak) activity.

p21-activated kinases in Erbb2-positive breast cancer: A new therapeutic target?

Rho family GTPase Chp/RhoV induces PC12 apoptotic cell death via JNK activation.

Pak1 regulates focal adhesion strength, myosin IIA distribution, and actin dynamics to optimize cell migration.

Sequential phosphorylation of SLP-76 at tyrosine 173 is required for activation of T and mast cells.

Rac1 drives melanoblast organization during mouse development by orchestrating pseudopod- driven motility and cell-cycle progression.

Inhibition or ablation of p21-activated kinase (PAK1) disrupts glucose homeostatic mechanisms in vivo.

Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A.

p21-activated kinase improves cardiac contractility during ischemia-reperfusion concomitant with changes in troponin-T and myosin light chain 2 phosphorylation.

Sumoylated protein tyrosine phosphatase 1B localizes to the inner nuclear membrane and regulates the tyrosine phosphorylation of emerin.

PKM2 enters the morpheein academy.

Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways.

Inhibition of p21 activated kinase (PAK) reduces airway responsiveness in vivo and in vitro in murine and human airways.

p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.

Mouse models of PAK function.

Pak2 kinase restrains mast cell FcεRI receptor signaling through modulation of Rho protein guanine nucleotide exchange factor (GEF) activity.

P-21-Activated Kinase 1 Mediates Gastrin-Stimulated Proliferation in the Colorectal Mucosa via Multiple Signalling Pathways.

The Rac GTPase effector p21 activated kinase is essential for hematopoietic stem/progenitor cell migration and engraftment.

The Tumor Suppressor Mst1 Promotes Changes in the Cellular Redox State by Phosphorylation and Inactivation of Peroxiredoxin-1.

Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells.

p21 activated kinase signaling coordinates glycoprotein receptor VI-mediated platelet aggregation, lamellipodia formation, and aggregate stability under shear.

Role of p21-activated kinases in cardiovascular development and function.

ArhGAP15, a Rac-specific GTPase-activating protein, plays a dual role in inhibiting small GTPase signaling.

The PAK system links Rho GTPase signaling to thrombin-mediated platelet activation.

Targeting Cdc42 in cancer.

FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.

p21-Activated kinase (PAK) regulates cytoskeletal reorganization and directional migration in human neutrophils.

Analysis of PTP1B sumoylation.

PAK signalling during the development and progression of cancer.

Activation of cAMP signaling attenuates impaired hepatic glucose disposal in aged male p21-activated protein kinase-1 knockout mice.

A Pak1/Erk signaling module acts through Gata6 to regulate cardiovascular development in zebrafish.

Pak2 is required for actin cytoskeleton remodeling, TCR signaling, and normal thymocyte development and maturation.

p21-activated kinase inhibitors.

Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers.

Gq-mediated Akt translocation to the membrane: a novel PIP3-independent mechanism in platelets.

Molecular pathways: targeting the kinase effectors of RHO-family GTPases.

Potential compensation among group I PAK members in hindlimb ischemia and wound healing.

Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiation.

Group I Paks as therapeutic targets in NF2-deficient meningioma.

Regulation of mammalian Ste20 (Mst) kinases.

Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization.

Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.

Disruption of p21-activated kinase 1 gene diminishes atherosclerosis in apolipoprotein E-deficient mice.

Pak2 Links TCR Signaling Strength to the Development of Regulatory T Cells and Maintains Peripheral Tolerance.

PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.

p21-Activated Kinase 2 Regulates Endothelial Development and Function through the Bmk1/Erk5 Pathway.

p21-activated kinase 2 regulates HSPC cytoskeleton, migration, and homing via CDC42 activation and interaction with β-Pix.

H-ras Inhibits the Hippo Pathway by Promoting Mst1/Mst2 Heterodimerization.

The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin.

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.

Hras helps hippo heterodimerize to evade tumor suppression.

Tuning PAK Activity to Rescue Abnormal Myelin Permeability in HNPP.

Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.

Group I Paks Promote Skeletal Myoblast Differentiation In Vivo and In Vitro.

Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.

Alfred G. Knudson Jr, MD, PhD: In Memoriam (1922-2016).

Targeting PAK1.

Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.

Recent advances in methods to assess the activity of the kinome.

An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.

Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

Pak1 mediates the stimulatory effect of insulin and curcumin on hepatic ChREBP expression.

Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.

Pak2 regulates myeloid-derived suppressor cell development in mice.

PTEN Deficiency and AMPK Activation Promote Nutrient Scavenging and Anabolism in Prostate Cancer Cells.

A new concept in NF2 pharmacotherapy: targeting fatty acid synthesis.

Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer.

How to get and keep your lab funded.